IBMS BoneKEy | Perspective
Anabolic therapy for osteoporosis: Calcilytics
Edward F Nemeth
DOI:10.1138/20080318
Abstract
Calcilytics are calcium receptor antagonists that stimulate the secretion of parathyroid hormone (PTH) from the parathyroid glands. Some calcilytics are orally bioavailable and can elicit a rapid and transient increase in circulating levels of endogenous PTH. Daily oral administration of a calcilytic compound to ovariectomized rats stimulates new bone formation and increases bone mineral density and biomechanical strength at cortical and cancellous sites. An orally-active calcilytic compound is currently being assessed for safety and efficacy in a Phase II clinical trial in postmenopausal women with osteoporosis. It can be anticipated that some of the safety and efficacy properties of exogenously administered PTH peptides will be shared with calcilytics, whereas others will be unique to these small molecule compounds.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.